title: ErbB3 and ErbB2/neu mediate the effect of heregulin on acetylcholine receptor gene expression in muscle: differential expression at the endplate.
abstract: Motor neurons modulate acetylcholine receptor (AChR) gene expression in skeletal muscle by two signalling pathways: the transmitter-evoked depolarization of muscle membrane inhibits AChR gene transcription throughout the myofibre presumably via activation of a serine/threonine kinase, while the transcription rates of AChR genes in the synaptic region are increased by nerve-derived trophic factors including AChR-inducing activity (ARIA). To gain further insight into these interactions we characterized the receptor for heregulin (HRG)/ARIA in muscle. We showed that HRG increases AChR alpha-subunit mRNA levels via tyrosine phosphorylation of ErbB3 and ErbB2/neu in myotubes. The protein tyrosine phosphatase inhibitor, pervanadate, potentiated the responses to HRG that were in turn blocked by the tyrosine kinase inhibitor erstatin, indicating the relevance of tyrosine phosphorylation to these events. The effects of HRG were inhibited by enhanced cellular serine/threonine phosphorylation which has been implicated in the repression of AChR genes by electrical activity. Immunocytochemical analysis of adult rat muscle revealed that while ErbB2/neu is present throughout the entire surface of the myofibre membrane, ErbB3 expression is exclusively restricted to the endplate suggesting its involvement in synapse-specific transcription of AChR genes by HRG/ARIA.
authors.affiliation: CNRS UA D1284 Neurobiologie Moléculaire, Institut Pasteur, Paris, France.
authors.forename: N
authors.initials: N
authors.lastname: Altiok
authors.forename: J L
authors.initials: JL
authors.lastname: Bessereau
authors.forename: J P
authors.initials: JP
authors.lastname: Changeux
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal; D015152:Blotting, Northern; D015153:Blotting, Western; D002352:Carrier Proteins / Q000494:pharmacology*; D002478:Cells, Cultured; D002642:Chick Embryo; D004815:Epidermal Growth Factor; D066246:ErbB Receptors / Q000378:metabolism* / Q000502:physiology*; D005455:Fluorescent Antibody Technique; D015870:Gene Expression / Q000187:drug effects; D006023:Glycoproteins / Q000494:pharmacology*; D046911:Macromolecular Substances; D051379:Mice; D009045:Motor Endplate / Q000378:metabolism*; D018482:Muscle, Skeletal / Q000378:metabolism*; D020890:Neuregulin-1; D011518:Proto-Oncogene Proteins / Q000378:metabolism* / Q000502:physiology*; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D020893:Receptor, ErbB-3; D011950:Receptors, Cholinergic / Q000032:analysis / Q000096:biosynthesis*; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D002352:Carrier Proteins; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D006023:Glycoproteins; D046911:Macromolecular Substances; D020890:Neuregulin-1; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D018719:Erb-b2 Receptor Tyrosine Kinases; D020893:Receptor, ErbB-3; D011950:Receptors, Cholinergic; D011994:Recombinant Proteins; C087230:heregulin beta1